Glucocorticoid effects on the programming of AT1b angiotensin receptor gene methylation and expression in the rat

Irina Bogdarina1, Andrea Haase, Simon Langley-Evans

  • 1Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Plos One
|February 20, 2010
PubMed

Insights

Maternal low protein diet during pregnancy can program offspring for hypertension by altering adrenal gene methylation. Treating pregnant rats with metyrapone reversed these epigenetic changes and prevented high blood pressure in offspring.

Area of Science:

  • Developmental programming
  • Epigenetics
  • Cardiovascular health

Background:

  • Adverse pregnancy events may program offspring for cardiovascular disease and hypertension.
  • The renin-angiotensin system plays a role in programmed hypertension.
  • Maternal low protein diet causes undermethylation of the angiotensin receptor gene (Agtr1b) promoter and its overexpression in offspring adrenal glands.

Purpose of the Study:

  • To investigate if maternal glucocorticoids modulate fetal DNA methylation and gene expression.
  • To determine if metyrapone, an 11beta-hydroxylase inhibitor, can prevent epigenetic and gene expression changes induced by maternal low protein diet.

Main Methods:

  • Rat dams were subjected to a low protein diet during pregnancy.
  • Offspring were treated with metyrapone or dexamethasone.
  • Adrenal Agtr1b methylation and gene expression were analyzed.
  • Offspring blood pressure was measured at 4 weeks of age.

Main Results:

  • Offspring of mothers on a low protein diet showed reduced adrenal Agtr1b methylation and increased gene expression.
  • Maternal treatment with metyrapone reversed these epigenetic changes and prevented hypertension in offspring.
  • Dexamethasone treatment in late pregnancy raised offspring blood pressure but did not affect Agtr1b methylation or expression.

Conclusions:

  • Maternal glucocorticoids in early pregnancy may induce Agtr1b gene methylation and expression changes, which are reversed by an 11beta-hydroxylase inhibitor.
  • The effects of glucocorticoids on Agtr1b methylation and expression may be stage-specific during pregnancy.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...